Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recognizing, reporting, and reducing adverse drug reactions.

S D Brown1, F J Landry

  • 1Department of Medicine, University of Vermont College of Medicine, and Fletcher Allen Health Care, Burlington, USA.

Southern Medical Journal
|May 3, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Titmuss et al. Immune Activation Following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study. <i>Int. J. Mol. Sci.</i> 2023, <i>24</i>, 5869.

International journal of molecular sciences·2024
Same author

Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study.

International journal of molecular sciences·2023
Same author

Robustly estimating the marginal likelihood for cognitive models via importance sampling.

Behavior research methods·2020
Same author

We are what we (think we) eat: The effect of expected satiety on subsequent calorie consumption.

Appetite·2020
Same author

Agents and spectres: Life-space on a medium secure forensic psychiatric unit.

Social science & medicine (1982)·2018
Same author

Physician views regarding the benefits and burdens of prenatal surgery for myelomeningocele.

Journal of perinatology : official journal of the California Perinatal Association·2017
Same journal

SMA's 6th Annual Physicians-in-Training Leadership Conference Abstract Presentations.

Southern medical journal·2026
Same journal

Potential Impact of Lower Federal Loan Availability on Medical Education in Appalachia.

Southern medical journal·2026
Same journal

Experiential Mentorship Skills Training: The Effect on Real-Life Mentoring.

Southern medical journal·2026
Same journal

Social Pressure: How Early Social Context Shapes Career Interest in Medicine.

Southern medical journal·2026
Same journal

Comparing Speed and Accuracy of Artificial Intelligence Large Language Models on the Orthopedic In-Training Examination.

Southern medical journal·2026
Same journal

Don't Wait to Talk about Weight: A 2-Hour Interactive Curriculum Improves Medical Student Skills with Weight Management.

Southern medical journal·2026
See all related articles

Adverse drug reactions (ADRs) are a significant cause of death, often underestimated due to underreporting. Improving ADR reporting and enhancing postmarketing surveillance by the Food and Drug Administration (FDA) can reduce these events.

Area of Science:

  • Pharmacovigilance
  • Public Health
  • Drug Safety

Background:

  • Adverse drug reactions (ADRs) are a serious public health concern, leading to significant morbidity and mortality.
  • Epidemiologic data indicate ADRs are a leading cause of death, yet they remain underreported.
  • Increasing media attention highlights the prevalence of ADRs and medication errors.

Purpose of the Study:

  • To underscore the underreported nature of ADRs and their impact on mortality.
  • To advocate for systemic changes at individual and national levels to reduce ADRs.
  • To emphasize the critical role of pharmacovigilance in mitigating drug-related harm.

Main Methods:

  • Review of epidemiologic evidence on ADRs and mortality.
  • Analysis of current reporting and documentation practices for ADRs.

Related Experiment Videos

  • Discussion of potential system-level interventions for ADR reduction.

    • Main Results:

    • ADRs are an underestimated cause of death, ranking as the fourth to sixth leading cause.
    • Current reporting mechanisms for ADRs are insufficient.
    • Public awareness of ADRs is growing.

    Conclusions:

    • Enhanced diligence in reporting and documenting ADRs at the individual level is crucial.
    • Expanding the postmarketing surveillance role of the Food and Drug Administration (FDA) is vital for national ADR reduction.
    • Systemic changes are necessary to effectively combat the burden of adverse drug reactions.